Organizer

Oct. 13 (Fri.) ,2017 15:00-17:00

Annex Hall
F203

Simultaneous Interpretation

【O-17】 Genome editing regulatory considerations and industrial application now and future

Since CRISPR-Cas, the bacterial acquired immune system, is suggested in 2012 to be used for genome editing, many companies and ventures strongly promote application of genome editing to medical and industrial fields. In this session, volunteers active in the front lines of genome-editing applications will deliver the talks on the genome editing regulatory considerations and industrial application now and future.

Coordinator

Osamu Nureki

Professor, Department of Biological Sciences, Graduate School of Science, The University of Tokyo

Structure-based development of genome-editing tool towards medical applications

Osamu Nureki

Professor, Department of Biological Sciences, Graduate School of Science, The University of Tokyo

Modelling the pathogenic effect of mutations in rare Mendelian conditions

Colin A. Johnson

Professor, University of Leeds

Genome/Transcriptome Editing technologies, based on PPR protein engineering

Takahiro NAKAMURA

Representative Director, EditForce

Targeted plant breeding applications of CRISPR-Cas technology

Neal Gutterson

Vice President of Research and Development, DuPont Pioneer

Close Window